Avid Bioservices Inc (CDMO)

[biopharm]

Omeros publishing "minimum" info regarding PS Targeting IP is important (if one listened closely, Omeros has much more info being held for confidentiality...and for any IIS contact I don't trust because I had no idea who he/she really was and again, will not listen to any to nicely request to stop mentioning certain puzzle pieces because Avid Bioservices BOD have failed to update their website and Stafford failed 100% for taking up the job to manipulate markets due to not getting all the information and playing dumb

_______

I wonder how far Roche will go, because Anita Kavlie had much info with her workings and NEW knowledge behind the late Dr Phil Thorpe that stirred up Big Pharma with his research and findings. Kyle also now at Halozyme

______


Patents by Inventor Anita Kavlie
Anita Kavlie has filed for patents to protect the following inventions.

This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

Compositions for Inhibiting MASP-2 Dependent Complement Activation
Publication number: 20190119402
Abstract: The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.
Type: Application
Filed: July 13, 2018
Publication date: April 25, 2019
Inventors: Thomas Dudler, Wayne R. Gombotz, James Brian Parent, Clark E. Tedford, Anita Kavlie, Urs Beat Hagemann, Herald Reiersen, Sergej Kiprijanov
ANTIBODIES AGAINST HUMAN ANGIOPOIETIN 2
Publication number: 20180282404
Abstract: The present invention relates to antibodies against human Angiopoietin 2 (anti-ANG-2 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Type: Application
Filed: February 28, 2018
Publication date: October 4, 2018
Applicant: Hoffmann-La Roche Inc.
Inventors: Ulrich Brinkmann, Remko Albert Griep, Klaus Kaluza, Anita Kavlie, Christian Klein, Joerg Thomas Regula, Werner Scheuer
Compositions for inhibiting MASP-2 dependent complement activation
Patent number: 10047165
Abstract: The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.
Type: Grant
Filed: September 13, 2016
Date of Patent: August 14, 2018
Assignee: Omeros Corporation
Inventors: Thomas Dudler, Wayne R. Gombotz, James Brian Parent, Clark E. Tedford, Anita Kavlie, Urs Beat Hagemann, Herald Reiersen, Sergej Kiprijanov
BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIES
Publication number: 20170369566
Abstract: The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Type: Application
Filed: May 23, 2017
Publication date: December 28, 2017
Applicant: Hoffmann-La Roche Inc.
Inventors: Monika Baehner, Ulrich Brinkmann, Guy Georges, Remko Albert Griep, Sabine Imhof-Jung, Anita Kavlie, Hubert Kettenberger, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Stefan Seeber, Markus Thomas
BISPECIFIC, BIVALENT ANTI-VEGF/ANTI-ANG-2 ANTIBODIES
Publication number: 20170240626
Abstract: The present invention relates to bispecific, bivalent antibodies against human vascular endothelial growth factor (VEGF/VEGF-A) and against human angiopoietin-2 (ANG-2), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Type: Application
Filed: October 4, 2016
Publication date: August 24, 2017
Applicant: Hoffmann-La Roche Inc.
Inventors: Monika Baehner, Sabine Imhof-Jung, Anita Kavlie, Hubert Kettenberger, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Kay-Gunnar Stubenrauch, Markus Thomas
...
...
...

https://patents.justia.com/inventor/anita-kavlie

_________

Patents Assigned to Affitech AS
ANTIBODIES
Publication number: 20160244527
Abstract: The present invention provides antibodies which bind to CXC chemokine receptor 4 (CXCR4) and which do not induce significant apoptosis of CXCR4 expressing cells. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.

Type: Application
Filed: May 11, 2016
Publication date: August 25, 2016
Applicant: AFFITECH RESEARCH AS
Inventors: Anita KAVLIE, Sergej Michailovic KIPRIJANOV
Anti-VEGF antibody compositions and methods
Patent number: 9421256
Abstract: Disclosed are human antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two primary VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new human antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate compositions and methods using the new VEGF-specific human antibodies are also provided.

Type: Grant
Filed: February 15, 2013
Date of Patent: August 23, 2016
Assignees: Affitech Research AS, Peregrine Pharmaceuticals, Inc.
Inventors: Anita Kavlie, Kyle Schlunegger

https://patents.justia.com/assignee/affitech-as

_________________


Anita Kavlie
Oslo University Hospital · Department of Pathology

Top co-authorsView all

Christian Klein
Head Oncology Programs & Department Head Cancer Immunotherapy Discovery at Roche Pharmaceutical Research and Early Development,

Ulrich Brinkmann
Roche

Markus Thomas

Philip E Thorpe
University of Texas Southwester

https://www.researchgate.net/profile/Anita_Kavlie/amp

_____________

Kyle, ex Peregrine sits over at Halozyme and there is much still to this day being well hidden from Peregrine shareholders and for the latest request that was sent on where Omeros came from...well, Peregrine collaborators and Roche

____________


Pharmexa announces further information about Affitech AS and Pharmexa A/S prior to the planned Extraordinary General Assembly in Pharmexa

April 7, 2009
...
...
An Alzheimer Disease vaccine (PX106) - licensed to the Danish pharmaceutical
company H. Lundbeck A/S. H. Lundbeck holds an exclusive global license for
PX106 for the treatment of Alzheimer's disease.

The strengths of the combined company
Affitech's proprietary antibody technology platform has been used successfully
to discover antibodies for several of its collaboration partners which included
Roche, Peregrine, Xoma, NatImmune, Viventia and Omeros. These technologies
include the Molecule-Based Antibody Screening or MBAS and Cell-Based Antibody
Selection or CBAS™ systems. Management believes that the CBAS system not gives
significant opportunities for the discovery of novel antibodies against cell
surface targets such as G-Protein-Coupled Receptors (GPCRs) but also against
cancer stem cell targets. With the recent consolidation in the antibody
discovery industry, the combined company is one of few remaining independent
players in the field.
...
...

https://www.globenewswire.com/news-release/2009/04/07/7764/0/en/Pharmexa-announces-further-information-about-Affitech-AS-and-Pharmexa-A-S-prior-to-the-planned-Extraordinary-General-Assembly-in-Pharmexa.html